Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yue Shentu

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Diabetes Care|October 14, 2011
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetesGary E Meininger, Russell Scott, Maria Alba, et al.
Journal of Diabetes|June 8, 2012
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetesWenying Yang, Yanfen Guan, Yue Shentu, et al.
Journal of Diabetes and Its Complications|November 3, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetesVivian Fonseca, Bart Staels, Jerry D Morgan, et al.
Journal of Diabetes|December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic controlRobert G Moses, Elizabeth Round, Yue Shentu, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand FrameworkEvgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
Clinical Lung Cancer|May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung CancerSalma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.
Plos One|April 23, 2009
Genetic structures of copy number variants revealed by genotyping single spermMinjie Luo, Xiangfeng Cui, David Fredman, et al.
Pharmaceutical Statistics|October 4, 2021
Estimands for overall survival in clinical trials with treatment switching in oncologyJuliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicR Daniel Meyer, Bohdana Ratitch, Marcel Wolbers, et al.
The New England Journal of Medicine|October 11, 2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerMartin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Diabetes Care|October 14, 2011
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetesGary E Meininger, Russell Scott, Maria Alba, et al.
Journal of Diabetes|June 8, 2012
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetesWenying Yang, Yanfen Guan, Yue Shentu, et al.
Journal of Diabetes and Its Complications|November 3, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetesVivian Fonseca, Bart Staels, Jerry D Morgan, et al.
Journal of Diabetes|December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic controlRobert G Moses, Elizabeth Round, Yue Shentu, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand FrameworkEvgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
Clinical Lung Cancer|May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung CancerSalma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.
Plos One|April 23, 2009
Genetic structures of copy number variants revealed by genotyping single spermMinjie Luo, Xiangfeng Cui, David Fredman, et al.
Pharmaceutical Statistics|October 4, 2021
Estimands for overall survival in clinical trials with treatment switching in oncologyJuliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicR Daniel Meyer, Bohdana Ratitch, Marcel Wolbers, et al.
The New England Journal of Medicine|October 11, 2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerMartin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.
Pageof 3